Teiko has developed an immune profiling platform using mass cytometry to revolutionize preclinical discovery and pharmaceutical development. Unlike conventional immune monitoring, Teiko uses metal-conjugated antibodies to profile >1 trillion unique cellular phenotypes in a single patient sample, a 1-billion-fold increase over flow cytometry. The end-to-end solution removes barriers to use mass cytometry analysis, to effectively identify promising drug targets and biomarkers to promote clinical trial success and expedite approval.